$ORMP

Oramed (NASDAQ: ORMP) CSO uses 435,084 shares to cover RSU tax

Oramed Pharmaceuticals Inc.'s Chief Scientific Officer, Miriam Kidron, reported a tax-related disposition of 435,084 common shares to cover tax withholding obligations from vested Restricted Stock Units. The shares were valued at $3.31 each. Following this transaction, Kidron directly holds 1,133,138 shares of Oramed common stock.

Original reporting
Published Apr 1, 2026, 2:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 1, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ORMP
Neutral
medium confidence
Mentioned
$ORMP
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$ORMPNeutralLow
01

Why it matters

This transaction is typical for insiders with vested RSUs and does not necessarily indicate a change in the company's fundamentals or outlook.

02

Market read

While notable, this insider activity is routine and unlikely to influence the stock's long-term trend significantly.

03

What to watch

The sale could be routine tax-related activity, and without additional negative signals, it should not be overinterpreted.

Timing: short-term

Background

Miriam Kidron, the Chief Scientific Officer of Oramed Pharmaceuticals, sold 435,084 shares to cover tax obligations from vested RSUs, valued at approximately $1,440,000.

Company-level read

Ticker impact

$ORMPNeutralMedium confidence
Context

The insider transaction involves a significant number of shares (435,084) used to cover tax obligations from vested RSUs, indicating ongoing insider confidence.

Expected impact

Minimal immediate impact; potential for slight short-term neutral to positive movement if viewed as routine.

Evidence & confidence

The sale is for tax purposes, not a sign of negative sentiment, but large insider sales can sometimes be viewed cautiously.

Market effects

Limited; the transaction is specific to insider tax planning and does not reflect sector-wide changes.

negligible

negligible

Counterpoint

Some investors may interpret large insider sales as a sign of potential upcoming challenges, warranting caution.

Key entities

  • Oramed Pharmaceuticals Inc.

    A biotechnology company focusing on oral drug delivery systems.

  • Miriam Kidron

    Chief Scientific Officer of Oramed Pharmaceuticals.

Related articles

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.